Norgine logo

Information intended for UK healthcare professionals only.

These promotional videos have been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines and Guidelines Live. See below for full disclaimer. Promotional information regarding Norgine Pharmaceutical Limited products will be presented.

View FERACCRU® (ferric maltol) prescribing information and adverse event reporting information here

A series of videos on the management of iron deficiency anaemia have been developed, that cover the following topics:

  • recent guidelines for the managment of iron deficiency anaemia in primary care
  • managing iron deficiency anaemia in primary care
  • managing iron deficiency anaemia in secondary care.

Recent guidelines for the management of iron deficiency anaemia in primary care

Dr Sophie Nelson —GP, Kenmore Medical Centre, Wilmslow

 

Managing iron deficiency anaemia in primary care

Dr Kevin Barrett —Clinical Lead for Gastroenterology at the Hertfordshire Valleys Clinical Commissioning Group (HVCCG) 

 

Managing iron deficiency anaemia in secondary care

Dr Fraser Cummings— Consultant Gastroenterologist at University Hospital Southampton

 

If you would like to talk to them, Norgine will be at Guidelines Live 2022

Click here to register for Guidelines live

 

These promotional videos have been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines and Guidelines Live. Norgine Pharmaceuticals Limited suggested the topics and presenters, who were paid an honorarium. Norgine Pharmaceuticals Limited carried out full medical approval on all materials to ensure compliance with regulations. The views and opinions of the presenters are not necessarily those of Guidelines, Guidelines Live, its publisher, advisers, or advertisers. No part of these videos may be reproduced in any form without the permission of the publisher.

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Norgine Pharmaceuticals Ltd on: Tel: +44 (0)1895 826 606. Email: medinfo@norgine.com

UK-HAE-FER-2200012

Date of preparation: May 2022